All the news at a glance

Datwyler looks at brake-by-wire technology, its composition, and the many benefits it can deliver to the mobility sector and its customers.

An ICCT report outlines the many planned phase-outs of Internal Combustion Engine vehicles across Europe out to the year 2040 and the opinion that car manufacturers should increasingly adapt product strategies away from ICE in favor of electric powered alternatives.

With the sale of the online distributor Reichelt to Invision, Datwyler will now be specialising solely in system-critical elastomer components.

Regardless of the technologies that are ultimately adopted on the road to a carbon neutral mobility sector, true success in this area will relate not only to the vehicle itself, but more so to the method of energy generation.

With twelve focus topics, the company aims to reduce its environmental footprint and create added value for all stakeholders.

We are pleased to invite you to our Capital Market Day 2021. You will get an exciting insight into the Datwyler world including a tour of our plant in nearby Schattdorf.

Despite the ongoing uncertainty caused by the pandemic, Datwyler has increased its forecasts for the year as a whole for revenue and EBIT margin to over CHF 1’150 million and above 16%, respectively.

The company will also showcase NeoFlex™ plungers and DuraCoat™ combiseals, which enable drug developers to protect the integrity of injectables throughout development to distribution.

From August 30-31, Datwyler will be hosting a 2-day virtual training course with the Parenteral Drug Association (PDA) on Characteristics of Pharmaceutical Elastomers and Aluminum Seals in Parenteral Packaging Systems.

We are thrilled to announce the return of our tradeshows in North America.

For years, Datwyler has been supporting the inhabitants of the surrounding villages through various community projects, thereby having a positive influence on the local environs.

As a founding member of the Alliance to Zero Datwyler aims net zero emissions across the pharmaceutical supply chain.